Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thrombomodulin alfa is a recombinant, soluble form of human thrombomodulin comprising all extracellular domains of the native protein. It acts as an anticoagulant by binding to thrombin, which then activates protein C. Activated protein C inactivates factors Va and VIIIa in the presence of cofactor protein S, thereby inhibiting further thrombin generation and clot extension. Thrombomodulin alfa also exhibits anti-inflammatory effects by activating thrombin–activatable fibrinolysis inhibitor and inhibiting neutrophil migration. It is primarily developed for the treatment of disseminated intravascular coagulation (DIC) and other blood clotting disorders such as thromboembolism[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thrombomodulin alfa.